The use of NMDA antagonists to attenuate vitreoretinal vascular endothelial growth factor (VEGF) protein levels in animals

摘要

Reducing the VEGF level in a patient suffering from an ocular disease or condition which is characterized by elevated VEGF and/or blood retina barrier (BRB) breakdown which comprises treating said patient with an effective amount of a compound selected from the group consisting of memantine, brimonidine and mixtures thereof.